(Q34213332)

31 July 2017

Back to the future: oral targeted therapy for RA and other autoimmune diseases (English)

1 reference

31 July 2017

Arian Laurence

2

0 references

Iain McInnes

object named as

Iain B McInnes

series ordinal

3

0 references

author name string

John J O'Shea

series ordinal

1

1 reference

PubMed ID

23419429

31 July 2017

language of work or name

English

0 references

publication date

19 February 2013

1 reference

Nature Reviews Rheumatology

31 July 2017

1 reference

31 July 2017

9

1 reference

31 July 2017

3

1 reference

31 July 2017

173-182

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.7

31 July 2017

0 references

cites work

Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Novel small-molecular therapeutics for rheumatoid arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Sorafenib in hepatocellular carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Kinase inhibitors: a new approach to rheumatoid arthritis treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

The tyrosine kinase network regulating mast cell activation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

A quantitative analysis of kinase inhibitor selectivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

p38 MAP kinase inhibitors: many are made, but few are chosen.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Targeting JNK for therapeutic benefit: from junk to gold?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Protein kinase C-theta (PKCtheta): it's all about location, location, location.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

The CD28 signaling pathway regulates glucose metabolism

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

MAP kinases in the immune response

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Antigen-presenting cells control T cell proliferation by regulating amino acid availability

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Phosphoinositide-regulated kinases and phosphoinositide phosphatases.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

MAP-kinase signaling pathways in T cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Calcium signaling mechanisms in T lymphocytes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Cyclosporine neurotoxicity: a review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Genetic analysis of B cell antigen receptor signaling

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

The Syk family of protein tyrosine kinases in T-cell activation and development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Jaks and STATs: biological implications

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Mast cell tumor necrosis factor alpha production is regulated by MEK kinases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Bruton's tyrosine kinase is a key regulator in B-cell development

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Signal transduction by the B cell antigen receptor and its coreceptors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Signal transduction by the T cell antigen receptor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

New insights into T-cell antigen receptor structure and signal transduction

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

JAKs and STATs in immunity, immunodeficiency, and cancer

5 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

JAK and STAT signaling molecules in immunoregulation and immune-mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Optimal case definitions of upper extremity disorder for use in the clinical treatment and referral of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Tec family kinases in inflammation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Tec family kinases: regulation of FcεRI-mediated mast-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

PKCθ: a new target for selective immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Protein kinase C inhibition ameliorates posttransplantation preservation injury in rat renal transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

IL-7 enhances the survival and maintains the size of naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Multiple sclerosis trial designs for the 21st century: building on recent lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

JNK is involved in signal integration during costimulation of T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Syk and Slp-76 mutant mice reveal a cell-autonomous hematopoietic cell contribution to vascular development.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4169143

Defective T Cell Differentiation in the Absence of Jnk1

28 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Defective lymphoid development in mice lacking Jak3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.7

Ruxolitinib: the first agent approved for myelofibrosis

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23419429

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2013.7

1 reference

PubMed ID

23419429

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference

PubMed ID

23419429